Podcast | Sjögren CCR East Lecture for Launch

Course Title for Certificate
Name

First NameLast Name
Email
example@example.com
What best describes your title?

Other
If PharmD, please enter your NABP ID#:
If PharmD, please enter your DOB:

MonthDayYear
2 digit month, 2 digit day, 4 digit yearDate
How many patients do you currently see each year regarding Sjogren’s disease?
How many years have you been in practice?
1. Which of the following factors has been identified as a key reason why prior rituximab trials in Sjögren's disease (SjD) may have failed to show efficacy, despite rituximab's ability to deplete peripheral B cells?
2. Ianalumab differs mechanistically from rituximab in its treatment of Sjögren's disease primarily because ianalumab:
3. According to current evidence and screening guidelines presented, which of the following statements best describes the approach to pulmonary involvement in patients with Sjögren's disease?
4. What are limitations of previous clinical trials studying improvement in Sjogren’s disease?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Discuss the updated understanding of pathophysiology, screening, diagnosis, and therapeutic targets of Sjögren’s disease
Analyze the most up to date evidence for B-cell depleting therapies, including that of a novel dual mechanism B-cell depletor and BAFF-R inhibitor, to improve the management of patients with Sjögren’s disease
Review the potential role of disease-modifying therapy (DMT) with novel B-cell depleting and dual mechanism therapies to improve patient quality of life and reduce disease burden in Sjögren’s disease

Please provide us with feedback regarding your experience at the activity:

Do you feel this activity was fair, balanced, and free of commercial bias?
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
What factors beyond clinical care that effect the health of your patients does your team experience?
Attestation:

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider #P0491).

AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of Continuing Pharmacy Education Credit (UAN #JA4008190-0000-26-013-H01-P).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
Date

MonthDayYear
2 digit month, 2 digit day, 4 digit yearDate
Credits
Should be Empty: